Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
02 September 2019 | Story Xolisa Mnukwa | Photo Xolisa Mnukwa
Shannon Arnold and Samkezi Mbalane
Shannon Arnold (left) and Samkezi Mbalane (right), the 2019 UFS recipients of the prestigious International Abe Bailey Travel Bursary.

The University of the Free State (UFS) has selected MPhil (African Studies) student and self-proclaimed ‘radical feminist’, Shannon Arnold, and former Golden Key UFS Qwaqwa Campus Chapter President and Political Studies and Governance honours student, Samkezi Mbalane, to represent the institution this year on the Abe Bailey Travel Bursary tour

The Abe Bailey Travel Bursary is a leadership-development programme that honours and targets university students or junior lecturers with a strong academic background, and who have shown exceptional qualities of leadership and service during their university careers as well as in a wider social context. Recipients of the bursary are expected to function as an integral part of a select and highly skilled group of individuals who will be embarking on a five-stage tour in December, starting in Cape Town (South Africa) and finishing in London (United Kingdom).

“Success comes from a feeling of satisfaction in what I have done for myself” – Shannon Arnold

Shannon Arnold, who is originally from Grahamstown, Eastern Cape, completed her undergraduate and honours studies in Political and International Studies and English Literature at Rhodes University. She moved to the UFS and is currently completing her transdisciplinary MPhil in African Studies, focused on Peace and Conflict in Post-conflict African Societies from a gendered perspective. 

“Moving to the Free State was an interesting cultural transition,” Arnold remarked. 
She further expressed how “pleasantly enlightened” she was by the UFS’s active and direct approach to transformation, and how it allowed her to spearhead and coordinate crucial student-movement initiatives such as the total shutdown protest which saw women and students march from the UFS Bloemfontein Campus to the Supreme Court of Appeal in 2018. Arnold believes that her passion, work, and experiences with community and service-based organisations against South Africa’s plight of gender-based violence has branded her a leader and qualified her for becoming an ‘Abe’.

Arnold grew up in a community-minded family and has thus been aligned with politics from a very young age. She is inspired by the thought of manifesting a reality where women in South Africa are able to pursue their own choices. She looks forward to exposing herself to foreign cultures on the tour to the UK, engaging with people who have like-minded convictions. 

“The desire and compassion to motivate and uplift others is what inspires me.”  – Samkezi Mbalane

Eastern Cape, Mount Fletcher-born Samkezi Mbalane, who graduated from the UFS with his undergraduate degree in Political Studies and Governance (Cum Laude), labels his life journey as ‘very difficult, yet fascinating’. 

Having been raised by a struggling single mother, he reflects on being dependant on other people in his immediate community for basic needs. He lived in a foster home for three years (Grade 10 to 12) as a means of survival. Mbalane explained that such experiences motivated him to pursue a career in politics, as he dreams of playing a pivotal role in the creation and implementation of South African governmental policies that will one day effectively benefit the poor.

Mbalane believes his claim to leadership came through ‘hard work and persistence’. He has served in various leadership positions, including President of the Golden Key Society UFS Qwaqwa Campus Chapter, Prime at Steve Biko Residence, active member of the Institute for Reconciliation and Social Justice, Enactus, and the Secretary General of the Student Parliament. Mbalane deemed being selected an ‘Abe’ as an “iconic opportunity for all aspirant leaders in South Africa.” 

He looks forward to working with people from different cultural backgrounds and career fields, but mostly, to seeing the world outside South Africa from a unique perspective.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept